Cross-sectional assessment of ultraviolet radiationerelated behaviors among young people after a diagnosis of melanoma or basal cell carcinoma
To the Editor: With recent increases in incidence rates of melanoma and nonmelanoma skin cancer (NMSC), especially in young people, skin cancer is important in survivorship research. Risk of multiple skin cancers may be associated with ultraviolet (UV) radiationerelated behaviors after a sentinel skin cancer. 1 Those in whom the disease is diagnosed at a young age have many at-risk years ahead and potentially higher genetic susceptibility. Though data on risk of a second skin cancer from UV is limited, 1 study found that patients with melanoma could reduce further melanoma risk by decreasing recreational sun exposure at any age. 2 A 2015 review found that melanoma survivors reported insufficient levels of sun protection. 3 A recent study of melanoma survivors who were 25 to 59 years of age at diagnosis, found that survivors had healthier behaviors than controls, but these were still suboptimal. 4 Protection behaviors, as well as outdoor and indoor tanning, among individuals with NMSC and younger patients with skin cancer are less well described. Therefore, we conducted an online survey of UV-related behaviors in young skin cancer survivors and evaluated predictors of engaging in these behaviors.
We enrolled individuals who, in the previous 1 to 5 years, had received a diagnosis of basal cell carcinoma (BCC) before age 40 or a diagnosis of stage I or II melanoma before age 50, spoke English, were non-Hispanic white, resided in Connecticut, and had Internet access. Yale University's institutional review board approved the study, and participants provided informed consent. Patients with BCC were recruited from a case-control study of early-onset BCC, 5 and 99 patients enrolled (response rate, 76.2%). We identified 268 patients with melanoma meeting our diagnosis criteria through the YaleeNew Haven Hospital Tumor Registry. A total of 135 patients with melanoma enrolled (response rate, 63.1%); 23 individuals who were ineligible were removed and 31 patients were unreachable. We calculated univariate differences by cancer type and evaluated independent predictors of the behaviors with multivariate logistic regression using SAS software (version 9.3, SAS Institute, Inc, Cary, NC).
One quarter of these patients with skin cancer (26.9%) reported sunbathing after diagnosis (Table I) . Six percent experienced a sunburn and 5.6% reported indoor tanning after diagnosis. When limited to the individuals who reported these exposures before their skin cancer, the prevalences of sunbathing, sunburn, and indoor tanning after diagnosis were 32.1%, 7.5%, and 9.0%, respectively. Skin cancer type was predictive of behaviors after diagnosis; individuals who had BCC were more likely to indoor tan, sunbathe, and report a sunburn than were those with melanoma (Table II) . Younger age and less worry about skin cancer were associated with sunbathing and practicing fewer than 3 protection behaviors. Among these young survivors, many sun protection behaviors were lacking, and their intentional exposure to natural and artificial UV was troublesome. Importantly, our study had pathologically confirmed skin cancer diagnoses, the lack of which is a limitation of national surveys. Few studies have evaluated predictors of UV-related behaviors, so more research is needed to understand behavioral predictors. Online data collection was used to minimize social desirability bias.
Because riskier UV-related behaviors were more common in younger survivors, those with NMSC, and those who did not worry about skin cancer, clinicians may need to target these individuals for multiple skin cancer risk reduction. Malignancy-associated dermatomyositis: Retrospective caseecontrol study from a single tertiary care center
To the Editor: Diagnosis of dermatomyositis often prompts malignancy screening. However, evidencebased malignancy screening guidelines are lacking. Two meta-analyses have investigated which malignancies occur with greater incidence in this population. 1, 2 One analysis highlights the need for more data from Western populations, especially the United States. 2 Hence, we characterized a malignancy-associated dermatomyositis cohort from a US tertiary care center.
An institutional review boardeapproved search of Cleveland Clinic's medical records led to the identification of malignancy-associated dermatomyositis patients. Inclusion required meeting Bohan and Peter dermatomyositis criteria. 3 Amyopathic dermatomyositis patients met Sontheimer criteria. 4 We compared this cohort with age-matched and sex-matched control dermatomyositis patients without malignancy and with $5 years follow-up from diagnosis.
We focused analyses on 50 patients (33 women, 17 men) with #3 years between dermatomyositis and malignancy diagnoses (Fig 1) . Average age at malignancy diagnosis was 58.5 years (median 6 standard deviation, 61.5 6 12.8 years), 58.3 years for classic dermatomyositis patients, and 50.1 years for amyopathic dermatomyositis patients. Malignancy distribution of the 50 patients were as follows: 9 lung, 7 colon, 6 breast, 5 hematologic, 4 oropharyngeal, 4 ovarian, 4 renal, 3 thyroid, 2 esophageal, 2 prostate, 1 thymic, 1 melanoma, 1 gastric, and 1 testicular. The most common malignancies were in accordance with meta-analyses results.
1,2 Thus, the risk-benefit ratio of dermatomyositis malignancy screening seems most favorable when focused on malignancies occurring with increased incidence in this population.
Of patients who developed malignancy after the dermatomyositis diagnosis (DM-MAL), 57.1% (16/ 28) had malignancy diagnosed #12 months and 75% (21/28) #2 years after the dermatomyositis diagnosis. The rates were similar for classic dermatomyositis (#12 months, 14/24 [58%]; #2 years, 17/24 [71%]) and amyopathic dermatomyositis (#12 months, 2/4 [50%]; #2 years, 4/4 [100%]). Thus, malignancy screening seemed most beneficial #12 months after dermatomyositis diagnosis and is possibly beneficial if repeated #3 years from diagnosis. Although some studies find increased malignancy risk [5 years after the dermatomyositis diagnosis, the costs and harms of screening [3 years afterward would likely result in an unfavorable risk-benefit ratio. However, larger and more focused studies are needed to determine cost-effectiveness of long-term malignancy screening for dermatomyositis patients.
Twenty-five of the 28 DM-MAL patients underwent testing for underlying malignancies after the dermatomyositis diagnosis. Of the patients with malignancies that do not occur with increased incidence in dermatomyositis ( gastric, tonsillar, thymic, thyroid), 4 of 5 (80%) patients (classic 3/4 [75%]; amyopathic 1/1 [100%]) had symptoms suggestive of those malignancies. Of the patients with malignancies that do occur with
